Shuttle Pharma's Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cel...
Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
Company Research
Source: Yahoo! Finance
development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the publication of a manuscript reporting on the ability of one of the Company's HDAC inhibitor pre-clinical assets, SP-1-303, which exhibits ataxia-telangiectasia mutated protein (ATM) activation and modulation of estrogen receptor expression resulting in substantial growth inhibition of estrogen receptor positive breast cancer cells (ER + BC). The published manuscript, titled "Dual-targeting class I HDAC inhibitor and ATM activator, SP-1-303, preferentially inhibits estrogen receptor positive breast cancer cell growth,” reports the work of Dr. Mira Jung, Professor of Radiation Medicine at Georgetown University Medical Center, and Dr. Scott Grindrod, Shuttle Pharma's Principal Scientist, and was published in PLOS ONE, a peer-reviewed open access journal published by the Public Library of Science (PLOS). SP-1-303, initially disco
Show less
Read more
Impact Snapshot
Event Time:
SHPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SHPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SHPH alerts
High impacting Shuttle Pharmaceuticals Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
SHPH
News
- Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with GlioblastomaGlobeNewswire
- Shuttle Pharma Announces Issuance of U.S. Patent for Selective Histone Deacetylase Inhibitors for the Treatment of Human DiseaseGlobeNewswire
- Shuttle Pharma Provides Second Quarter 2024 Corporate UpdateGlobeNewswire
- Shuttle Pharma Regains Compliance with Nasdaq Minimum Bid Price RequirementGlobeNewswire
- Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1) [Yahoo! Finance]Yahoo! Finance
SHPH
Sec Filings
- 9/20/24 - Form S-1
- 9/16/24 - Form 424B3
- 9/13/24 - Form 8-K
- SHPH's page on the SEC website